A standout stock in the healthcare sector last year, Novo Nordisk (NVO 3.87%) isn't doing too badly so far in the embryonic days of 2024. On Thursday -- yet another gloomy day for the market when the S&P 500 index dipped by 0.3% -- the drugmaker's share price closed nearly 4% higher. Sparking that upbeat investor interest was news of a pair of research collaboration deals. A pair of research collaboration deals On Thursday morning, Novo Nordisk divulged that it had inked new arrangements with two U.S. biote ...